Lyrica Pfizer Inc. - Treatment for Neuropathic Pain
Lyrica is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to gabapentin (Neurontin). Lyrica is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).Posted: December 2004
Related articles
- FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions - October 12, 2017
- FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review - June 21, 2012
- FDA Approves First Drug for Treating Fibromyalgia - Lyrica - June 22, 2007
- Pfizer Statement on Regulatory Status of Lyrica - September 2, 2004
Lyrica (pregabalin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
